Skip to main content
OpenTrials

Clinical trial condition

EGFR NP_005219.2:p.L858R

Explore clinical trials studying EGFR NP_005219.2:p.L858R. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies
Refine in advanced search Browse all conditions

EGFR NP_005219.2:p.L858R trial results

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

NCT01532089

Conditions
EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma, +1 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Heartland Cancer Research NCORP Decatur, Illinois, United States
  • Illinois CancerCare-Peoria Peoria, Illinois, United States
  • Carle Cancer Center NCI Community Oncology Research Program Urbana, Illinois, United States
View all 19 locations
View Trial Details

Related conditions